Cervical Cancer Clinical Trials (as of October 2017)

ENGOT-cx8/BGOG

Leading group: BGOG

Clinical Trial Study: A multi-cohort, randomized phase I/II trial investigating the efficacy and safety of Tisotumab Vedotin as monotherapy and in combination in previously untreated subjects with reccurent or metastatic cervical cancer

Number of patients accrued: 0

Planned number of patients: 120

Participating groups: TBA

Planned start in 2018

 

  

ENGOT-cx7/NSGO/cc1-MaRuC

Leading group: NSGO

Clinical Trial Study: A randomized double-blind placebo-controlled phase II trial of Rucaparib maintenance therapy for patienst with locally advanced cancer - MaRuC

Number of patients accrued: 0

Planned number of patients: 162

Participating groups: 

BGOG, Cancer Trials Ireland, CEEGOG, EORCT, GEICO, ISGO, MITO, NCRI, NOGGO, PGOG

Planned start in 2Q 2018

 

 

ENGOT-cx6/BGOG-cx6/GCT1015-04

Leading group: BGOG

Clinical Trial Study: GCT1015-04: A single arm, multicenter, phase IIb trial investigating the efficacy of Tisotumab Vedotin (HuMax-TF-ADC) therapy in patients with recurrent or metastatic cervical cancer with disease progression after first line therapy

Number of patients accrued: 0

Planned number of patients: 100

Participating groups: TBA

Planned start in 2018

 

 

ENGOT-cx5/A-AGO/ADVANCE

Leading group: A-AGO

Clinical Trial Study: ADVANCE (ADVAxis Immunotherapy with Nivolumab to treat recurrent or metastatic CErvical Cancer), A randomized phase II study to evaluate the safety and efficacy of ADXS-602 in combination with Nivolumab

Number of patients accrued: 0

Planned number of patients: 460

Participating groups: TBA

Planned start in 2018

 

 

ENGOT-cx4/GINECO/SENTICOL

Leading group: GINECO

Clinical Trial Study: International prospective validation trial of sentinel node biopsy in cervical cancer

Number of patients accrued: 0

Planned number of patients: 950

Participating groups: TBA

Planned start in 2018

 

 

ENGOT-cx3/CEEGOG/ABRAX

Leading group: CEEGOG

Clinical Trial Study: Abandoning of radical hysterectomy in cervical cancer - retrospective trial

Number of patients accrued: 0

Planned number of patients: TBA

Participating groups: 

AGO, BGOG, MITO

Planned start in 2018

 

 

ENGOT-cx2/CEEGOG/SENTIX

Leading group: CEEGOG

Clinical Trial Study: SENTIX (SENTinel lymph node in cervIX cancer) - a prospective observational trial on sentinel lymph node biopsy in patients with early stage cervical cancer

Number of patients accrued: 159

Planned number of patients: 350

Participating groups:

BGOG, other TBA

 

 

ENGOT-cx1/BGOG-cx1

Leading group: BGOG

Clinical Trial Study: A randomized phase II trial of paclitaxel-carboplatin 3-weekly with or without Nintedanib (BIBFI 120) in advanced or recurrent cervical carcinoma

Number of patients accrued: 70

Planned number of patients: 120

Participating groups:

AGO, GEICO, MaNGO, MITO, NCRI, NOGGO

 

 

Up Coming ENGOT Meeting

Naples, Italy, April 19-20, 2018

Don't miss out on the latest updates

Save the Date!

You May Also Like

GCA WORKSHOPS

Watch the Webcasts 

 

Read More

CLINICAL TRIALS

Latest Published Research

 

Read More

FOR PATIENTS

Key Insights

 

Read More

ESGO 2018

State of the Art Conference

 

Read More